改良预装载输送系统用于开窗腔内主动脉修复的跨大西洋多中心研究
该多中心回顾性单臂队列研究纳入欧美16中心712例择期行开窗腔内修复的复杂腹主动脉瘤或胸腹主动脉瘤患者,使用Cook改良预装载输送系统(MPDS),技术成功率96.1%,30天死亡率4.8%,12个月和24个月免于再干预率分别为87.1%和79.2%。作者认为MPDS安全有效,可减小对侧鞘管尺寸并获良好结果。
要点
- 712例择期开窗腔内修复中,技术成功率96.1%,30天死亡4.8%。
- 对侧股鞘平均15F±4,41例(6.7%)鞘管≤8F。
- 12和24个月免于再干预率87.1%和79.2%,靶血管通畅率98.6%和96.8%。
核心结论
- 作者认为MPDS安全有效,总体获益包括在复杂解剖治疗中减小对侧鞘管尺寸并获得良好结果。
研究设计与样本
- 多中心回顾性单臂队列研究,纳入欧洲和美国16个中心所有连续择期使用MPDS开窗装置(Cook Medical)行复杂腹主动脉瘤或胸腹主动脉瘤修复的患者。
主要发现
- 共712例患者(中位年龄73岁,IQR 68-78岁,83%男性),35.4%(n=252)为胸腹主动脉瘤,64.6%(n=460)为复杂腹主动脉瘤修复。
- 共纳入2755根靶血管(平均每例3.9根),其中1628根经同侧预装载MPDS置入(1440根经双端口手柄,188根经上方)。
- 靶血管插管时对侧股鞘平均尺寸15F±4,41例(6.7%)鞘管尺寸≤8F;技术成功率96.1%。
- 中位手术时间209分钟(IQR 161-270分钟),对比剂体积100 mL(IQR 70-150 mL),透视时间63.9分钟(IQR 49.7-80.4分钟),中位累积空气比释动能辐射剂量2630 mGy(IQR 838-5251 mGy)。
- 30天死亡率4.8%(n=34),入路并发症6.8%(n=48),30天再干预7%(n=50,其中18例分支相关)。
关键数值与推荐
- 628例(88%)有>30天随访,中位随访19个月(IQR 8-39个月);分支相关内漏(Ic/IIIc型)15例(2.6%),动脉瘤增长>5 mm 54例(9.5%)。
- 12和24个月免于再干预率分别为87.1%(SE 1.5%)和79.2%(SE 2.0%)。
- 12和24个月总体靶血管通畅率分别为98.6%(SE 0.3%)和96.8%(SE 0.4%);经MPDS下方支架置入的动脉分别为97.9%(SE 0.4%)和95.3%(SE 0.8%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Analyze the outcomes of endovascular complex abdominal and thoracoabdominal aortic aneurysm repair using the Cook fenestrated device with the modified preloaded delivery system (MPDS) with a biport handle and preloaded catheters. METHODS: A multicenter retrospective single arm cohort study was performed, including all consecutive patients with complex abdominal aortic aneurysm repair and thoracoabdominal aortic aneurysms treated with the MPDS fenestrated device (Cook Medical). Patient clinical characteristics, anatomy, and indications for device use were collected. Outcomes, classified according to the Society for Vascular Surgery reporting standards, were collected at discharge, 30 days, 6 months, and annually thereafter. RESULTS: Overall, 712 patients (median age, 73 years; interquartile range [IQR], 68-78 years; 83% male) from 16 centers in Europe and the United States treated electively were included: 35.4% (n = 252) presented with thoracoabdominal aortic aneurysms and 64.6% (n = 460) with complex abdominal aortic aneurysm repair. Overall, 2755 target vessels were included (mean ,3.9 per patient). Of these, 1628 were incorporated via ipsilateral preloads using the MPDS (1440 accessed from the biport handle and 188 from above). The mean size of the contralateral femoral sheath during target vessel catheterization was 15F ± 4, and in 41 patients (6.7%) the sheath size was ≤8F. Technical success was 96.1%. Median procedural time was 209 minutes (IQR, 161-270 minutes), contrast volume was 100 mL (IQR, 70-150mL), fluoroscopy time was 63.9 minutes (IQR, 49.7-80.4 minutes) and median cumulative air kerma radiation dose was 2630 mGy (IQR, 838-5251 mGy). Thirty-day mortality was 4.8% (n = 34). Access complications occurred in 6.8% (n = 48) and 30-day reintervention in 7% (n = 50; 18 branch related). Follow-up of >30 days was available for 628 patients (88%), with a median follow-up of 19 months (IQR, 8-39 months). Branch-related endoleaks (type Ic/IIIc) were observed in 15 patients (2.6%) and aneurysm growth of >5 mm was observed in 54 (9.5%). Freedom from reintervention at 12 and 24 months was 87.1% (standard error [SE],1.5%) and 79.2% (SE, 2.0%), respectively. Overall target vessel patency at 12 and 24 months was 98.6% (SE, 0.3%) and 96.8% (SE, 0.4%), respectively, and was 97.9% (SE, 0.4%) and 95.3% (SE, 0.8%) for arteries stented from below using the MPDS, respectively. CONCLUSIONS: The MPDS is safe and effective. Overall benefits include a decrease in contralateral sheath size in the treatment of complex anatomies with favorable results.
引用
- Tsilimparis N, Gouveia E Melo R, Schanzer A, et al. Transatlantic multicenter study on the use of a modified preloaded delivery system for fenestrated endovascular aortic repair. J Vasc Surg. 2023. PMID: 37330705. doi:10.1016/j.jvs.2023.05.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。